BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 28254873)

  • 1. Inter- and Intraobserver Agreement of
    Ohira H; Ardle BM; deKemp RA; Nery P; Juneau D; Renaud JM; Klein R; Clarkin O; MacDonald K; Leung E; Nair G; Beanlands R; Birnie D
    J Nucl Med; 2017 Aug; 58(8):1324-1329. PubMed ID: 28254873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of Myocardial 18F-FDG Uptake Through Prolonged High-Fat, High-Protein, and Very-Low-Carbohydrate Diet Before FDG-PET/CT for Evaluation of Patients With Suspected Cardiac Sarcoidosis.
    Lu Y; Grant C; Xie K; Sweiss NJ
    Clin Nucl Med; 2017 Feb; 42(2):88-94. PubMed ID: 27922863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Impact of Extent, Severity, and Heterogeneity of Abnormalities on
    Sperry BW; Tamarappoo BK; Oldan JD; Javed O; Culver DA; Brunken R; Cerqueira MD; Hachamovitch R
    JACC Cardiovasc Imaging; 2018 Feb; 11(2 Pt 2):336-345. PubMed ID: 28823747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis.
    Blankstein R; Osborne M; Naya M; Waller A; Kim CK; Murthy VL; Kazemian P; Kwong RY; Tokuda M; Skali H; Padera R; Hainer J; Stevenson WG; Dorbala S; Di Carli MF
    J Am Coll Cardiol; 2014 Feb; 63(4):329-36. PubMed ID: 24140661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Utility of Whole Body
    Giudicatti L; Marangou J; Nolan D; Dembo L; Baumwol J; Dwivedi G
    Heart Lung Circ; 2020 Jan; 29(1):e1-e6. PubMed ID: 31501049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual findings of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with cardiac sarcoidosis.
    Ito K; Okazaki O; Morooka M; Kubota K; Minamimoto R; Hiroe M
    Intern Med; 2014; 53(18):2041-9. PubMed ID: 25224185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppressing physiologic 18-fluorodeoxyglucose uptake in patients undergoing positron emission tomography for cardiac sarcoidosis: The effect of a structured patient preparation protocol.
    Christopoulos G; Jouni H; Acharya GA; Blauwet LA; Kapa S; Bois J; Chareonthaitawee P; Rodriguez-Porcel MG
    J Nucl Cardiol; 2021 Apr; 28(2):661-671. PubMed ID: 31111450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrid Magnetic Resonance Imaging and Positron Emission Tomography With Fluorodeoxyglucose to Diagnose Active Cardiac Sarcoidosis.
    Dweck MR; Abgral R; Trivieri MG; Robson PM; Karakatsanis N; Mani V; Palmisano A; Miller MA; Lala A; Chang HL; Sanz J; Contreras J; Narula J; Fuster V; Padilla M; Fayad ZA; Kovacic JC
    JACC Cardiovasc Imaging; 2018 Jan; 11(1):94-107. PubMed ID: 28624396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (18)F-FDG PET/CT for the assessment of myocardial sarcoidosis.
    Skali H; Schulman AR; Dorbala S
    Curr Cardiol Rep; 2013 May; 15(5):352. PubMed ID: 23504346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis.
    Ahmadian A; Pawar S; Govender P; Berman J; Ruberg FL; Miller EJ
    J Nucl Cardiol; 2017 Apr; 24(2):413-424. PubMed ID: 27457527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Same day comparison of PET/CT and PET/MR in patients with cardiac sarcoidosis.
    Wisenberg G; Thiessen JD; Pavlovsky W; Butler J; Wilk B; Prato FS
    J Nucl Cardiol; 2020 Dec; 27(6):2118-2129. PubMed ID: 30603887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reproducibility of cardiac magnetic resonance imaging in patients referred for the assessment of cardiac sarcoidosis; implications for clinical practice.
    Juneau D; Nery PB; Pena E; Inácio JR; Beanlands RSB; deKemp RA; Alhajari ZM; Spence S; Medor MC; Dwivedi G; Birnie D
    Int J Cardiovasc Imaging; 2020 Nov; 36(11):2199-2207. PubMed ID: 32613384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of
    Manabe O; Ohira H; Hirata K; Hayashi S; Naya M; Tsujino I; Aikawa T; Koyanagawa K; Oyama-Manabe N; Tomiyama Y; Magota K; Yoshinaga K; Tamaki N
    Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1240-1247. PubMed ID: 30327855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial FDG-PET scans help to identify steroid resistance in cardiac sarcoidosis.
    Shelke AB; Aurangabadkar HU; Bradfield JS; Ali Z; Kumar KS; Narasimhan C
    Int J Cardiol; 2017 Feb; 228():717-722. PubMed ID: 27886616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of heparin loading during an 18F-FDG PET/CT examination to search for cardiac sarcoidosis activity.
    Ito K; Morooka M; Okazaki O; Minaminoto R; Kubota K; Hiroe M
    Clin Nucl Med; 2013 Feb; 38(2):128-30. PubMed ID: 23334129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (18)F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis: results of a preliminary prospective study.
    Ambrosini V; Zompatori M; Fasano L; Nanni C; Nava S; Rubello D; Fanti S
    Clin Nucl Med; 2013 Apr; 38(4):e171-7. PubMed ID: 23429384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Right ventricular (18)F-FDG uptake is an important indicator for cardiac involvement in patients with suspected cardiac sarcoidosis.
    Manabe O; Yoshinaga K; Ohira H; Sato T; Tsujino I; Yamada A; Oyama-Manabe N; Masuda A; Magota K; Nishimura M; Tamaki N
    Ann Nucl Med; 2014 Aug; 28(7):656-63. PubMed ID: 24889126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of quantitative assessment of cardiac
    Lebasnier A; Legallois D; Bienvenu B; Bergot E; Desmonts C; Zalcman G; Agostini D; Manrique A
    Ann Nucl Med; 2018 Jun; 32(5):319-327. PubMed ID: 29560563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial (18)F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis.
    Manabe O; Yoshinaga K; Ohira H; Masuda A; Sato T; Tsujino I; Yamada A; Oyama-Manabe N; Hirata K; Nishimura M; Tamaki N
    J Nucl Cardiol; 2016 Apr; 23(2):244-52. PubMed ID: 26243179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of myocardial 2-[18F]fluoro-2-deoxy-D-glucose uptake is a typical feature in cardiac sarcoidosis: a study of 231 patients.
    Schildt JV; Loimaala AJ; Hippeläinen ET; Ahonen AA
    Eur Heart J Cardiovasc Imaging; 2018 Mar; 19(3):293-298. PubMed ID: 28950301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.